Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS)....
LY-3541860 by Eli Lilly and Co for Autoimmune Disorders: Likelihood of Approval
LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders. According to...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's LY-3541860?
LY-3541860 is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Relapsing Multiple...